Drug Insights

Maximize Your Synapse Use: Your Guide to Searching Indomethacin

27 March 2024
2 min read

Indomethacin, a diminutive molecule that belongs to the illustrious class of nonsteroidal anti-inflammatory drugs (NSAIDs), works by inhibiting the COX enzyme, thereby impeding inflammation and pain. This drug, can be used for a vast spectrum of maladies including ductus arteriosus, periarthritis, tennis elbow, acute brachial neuritis, gouty arthritis, ankylosing spondylitis, bursitis, tendinopathy, osteoarthritis, rheumatoid arthritis, tumescence, pain, elbow tendinopathy, inflammation, and musculoskeletal pain, is celebrated for its versatility. The roots of this pioneering drug, originally cultivated by the esteemed iROKO Partners Ltd., can be traced back to June 1965, when it first received its approval. With its COX inhibiting properties, indomethacin engenders a plethora of benefits by effectively mitigating inflammation and providing pain relief in a wide range of conditions. Click on the image below to begin the exploration journey of Indomethacin through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves Vertex's Clinical Trials for ADPKD Drug VX-407
Latest Hotspot
3 min read
FDA Approves Vertex's Clinical Trials for ADPKD Drug VX-407
26 March 2024
Vertex has received authorization from the FDA to proceed with clinical trials for VX-407, a new drug candidate targeting the management of ADPKD.
Read →
AstraZeneca's Strategic Layout for Targeting PTH1R in the Treatment of Hypoparathyroidism
Hot Spotlight
9 min read
AstraZeneca's Strategic Layout for Targeting PTH1R in the Treatment of Hypoparathyroidism
26 March 2024
On March 14, AstraZeneca plans to buy Amolyt Pharma, a biotech firm specializing in rare endocrine disorders, enhancing its Alexion unit with the phase III drug, eneboparatide, for hypoparathyroidism treatment.
Read →
Sosei Heptares Regains Full Rights to Oral GPR35 Activator HTL0027477 from GSK for Inflammatory Bowel Trials
Latest Hotspot
3 min read
Sosei Heptares Regains Full Rights to Oral GPR35 Activator HTL0027477 from GSK for Inflammatory Bowel Trials
26 March 2024
Sosei Heptares reclaims complete control over HTL0027477 from GSK, a pioneering oral GPR35 activator set for clinical trials in treating inflammatory bowel conditions.
Read →
Master Loperamide Search on Synapse
Drug Insights
2 min read
Master Loperamide Search on Synapse
26 March 2024
Loperamide, an FDA-approved small molecule drug since December 1976, is a puzzling substance that binds to opioid receptors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.